An efficacy trial of the malaria vaccine SPf66 in Gambian infants - Second year of follow-up

K. A. Bojang, S. K. Obaro, U. D'Alessandro, S. Bennett, P. Langerock, G. A.T. Targett, B. M. Greenwood

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


In 1994, 630 Gambian infants were immunized with three doses of the synthetic polypeptide malaria vaccine SPf66 or with a control vaccine. No significant protection against first or total attacks of malaria was observed among the children who received SPf66. However, the period of follow-up was short. Thus, 532 children were followed for a second malaria transmission season during which 291 episodes of malaria were detected. Protective efficacies of SPf66 against first attacks of malaria and against all attacks of malaria were 8% [95% CI - 20%, 30%] and 2% [95% CI - 26% 24%] respectively. SPf66 did not provide any significant degree of protection to Gambian infants during a second year of follow-up.

Original languageEnglish (US)
Pages (from-to)62-67
Number of pages6
Issue number1
StatePublished - Jan 1 1998
Externally publishedYes


  • Malaria
  • Malaria vaccine
  • Plasmodium falciparum
  • Spf66

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases


Dive into the research topics of 'An efficacy trial of the malaria vaccine SPf66 in Gambian infants - Second year of follow-up'. Together they form a unique fingerprint.

Cite this